13F-HR: Johnson & Johnson Reveals Q2 2024 Investment Portfolio in Form 13F Filing

Johnson & Johnson's latest 13F filing discloses its holdings as of June 30, 2024, revealing significant investments in various biotech and pharmaceutical companies.

Summary

• Johnson & Johnson filed its Form 13F for the quarter ended June 30, 2024.
• The filing details the company's holdings, with a total value of $400,670,584 across 20 entries.
• The report includes holdings managed by both Johnson & Johnson and Johnson & Johnson Innovation JJDC, Inc.
• The filing lists the number of shares held for each company, along with their corresponding value.
• The investment decisions are under the discretion of the investment manager.
• The filing confirms that Johnson & Johnson holds shares in several biotech and pharmaceutical companies.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document is a standard portfolio disclosure, indicating ongoing investment activity in the biotech and pharmaceutical sectors. The large portfolio value suggests a strong financial position and commitment to innovation.

Positives

• The filing provides transparency into Johnson & Johnson's investment strategy in the biotech and pharmaceutical sectors.
• The diverse portfolio suggests a strategic approach to investing in various therapeutic areas and technologies.
• The significant investment values indicate a strong commitment to supporting innovation in healthcare.

Risks

• The value of the holdings is subject to market fluctuations and the performance of the individual companies.
• Investments in biotech and pharmaceutical companies carry inherent risks related to drug development, regulatory approvals, and market competition.

Future Outlook

The document does not contain specific forward-looking statements, but the investment portfolio reflects Johnson & Johnson's strategic interests in the biotech and pharmaceutical industries.

Industry Context

Johnson & Johnson's investment portfolio reflects the broader industry trend of pharmaceutical companies investing in smaller biotech firms to access innovative technologies and drug candidates. This strategy allows larger companies to diversify their pipelines and mitigate the risks associated with internal research and development.

Comparison to Industry Standards

• Johnson & Johnson's investment strategy is similar to other large pharmaceutical companies like Pfizer, Novartis, and Roche, which also maintain venture capital arms or strategic investment funds.
• These companies often invest in early-stage biotech companies to gain access to promising technologies and therapies.
• The size of Johnson & Johnson's portfolio, at approximately $400 million, is within the range of similar investment portfolios managed by other major pharmaceutical firms.

Stakeholder Impact

• Shareholders: Provides insight into the company's investment strategy.
• Employees: Supports innovation and growth within the healthcare sector.
• Customers: Potentially leads to the development of new therapies and treatments.
• Suppliers: Creates opportunities for collaboration and partnerships.
• Creditors: Reinforces the company's financial stability.

Key Dates